Drugs that contain Osilodrostat Phosphate

1. Drug name - ISTURISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(3 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(6 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(8 years from now)

CN105440038A RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Feb, 2019

(3 years ago)

CN101248078B RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN102408429A RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole And Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN101248078A RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

CN102408429B RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN102711916B RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

CN102711916A RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

IN200800733P1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

IN265497B RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP1919916B1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP2256118B1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases
Aug, 2026

(3 years from now)

EP1919916A1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP1919916B8 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP2256118A1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases
Aug, 2026

(3 years from now)

EP2523731A1 RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

EP2523731B1 RECORDATI RARE Use Of An Adrenal Hormone-Modifying Agent
Jan, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent Jan, 2031

(8 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms Oct, 2035

(13 years from now)

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.